Zeformin XR 30 Tablet is a combination oral antidiabetic medication containing Gliclazide 30 mg and Metformin 500 mg, designed for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by reducing hepatic glucose production and enhancing peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The extended-release formulation of Zeformin XR ensures a gradual release of active ingredients, promoting sustained plasma concentration, minimizing gastrointestinal side effects, and enhancing patient compliance through once-daily dosing. This combination therapy is indicated for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve optimal glycemic targets. Zeformin XR should be used with caution in patients with renal or hepatic impairment, and regular monitoring of blood glucose levels, renal function, and lactic acidosis risk is recommended. It is contraindicated in patients with known hypersensitivity to its components, severe renal dysfunction, or conditions predisposing to hypoxia. Adherence to prescribed dosage and lifestyle modifications is essential for effective diabetes management and reduction of long-term complications associated with hyperglycemia.